(19)
(11) EP 3 437 663 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
18.06.2025 Bulletin 2025/25

(45) Mention of the grant of the patent:
02.04.2025 Bulletin 2025/14

(21) Application number: 17775674.9

(22) Date of filing: 28.02.2017
(51) International Patent Classification (IPC): 
A61K 48/00(2006.01)
A61K 8/60(2006.01)
G01N 33/50(2006.01)
A61K 31/713(2006.01)
A23L 33/13(2016.01)
G01N 33/68(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/713; A23L 33/13; G01N 33/5023; G01N 33/5044; G01N 2333/4742; A61Q 19/00; A61K 8/606
(86) International application number:
PCT/KR2017/002211
(87) International publication number:
WO 2017/171249 (05.10.2017 Gazette 2017/40)

(54)

A NON-THERAPEUTIC USE OF A COMPOSITION FOR MOISTURIZING SKIN OR STRENGTHENING SKIN BARRIER FUNCTION BY PROMOTING DIFFERENTIATION OF SKIN CELLS

NICHT-THERAPEUTISCHE VERWENDUNG EINER ZUSAMMENSETZUNG ZUR MOISURISIERUNG VON HAUT ODER ZUR VERSTÄRKUNG DER HAUTBARRIEREFUNKTION DURCH FÖRDERUNG DER DIFFERENZIERUNG VON HAUTZELLEN

UTILISATION NON THÉRAPEUTIQUE D'UNE COMPOSITION POUR HYDRATER LA PEAU OU RENFORCER LA FONCTION DE BARRIÈRE CUTANÉE EN FAVORISANT LA DIFFÉRENCIATION DES CELLULES CUTANÉES


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 28.03.2016 KR 20160036834

(43) Date of publication of application:
06.02.2019 Bulletin 2019/06

(73) Proprietor: Amorepacific Corporation
Seoul 04386 (KR)

(72) Inventors:
  • SON, Eui Dong
    Yongin-si Gyeonggi-do 17074 (KR)
  • KIM, Hyoung June
    Yongin-si Gyeonggi-do 17074 (KR)
  • KIM, Kyu Han
    Yongin-si Gyeonggi-do 17074 (KR)
  • PARK, Sun Young
    Yongin-si Gyeonggi-do 17074 (KR)
  • LEE, Sung Hoon
    Yongin-si Gyeonggi-do 17074 (KR)
  • CHOI, Min Sik
    Yongin-si Gyeonggi-do 17074 (KR)
  • CHO, Eun-Gyung
    Yongin-si Gyeonggi-do 17074 (KR)
  • LEE, Tae Ryong
    Yongin-si Gyeonggi-do 17074 (KR)

(74) Representative: Novagraaf Technologies 
Bâtiment O2 2, rue Sarah Bernhardt CS90017
92665 Asnières-sur-Seine Cedex
92665 Asnières-sur-Seine Cedex (FR)


(56) References cited: : 
WO-A1-2006/031210
WO-A1-2014/167030
   
  • RYUTA MUROMOTO ET AL: "Jun Activation Domain-binding Protein 1 (JAB1) Is Required for the Optimal Response to Interferons", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 288, no. 43, 25 October 2013 (2013-10-25), US, pages 30969 - 30979, XP055619799, ISSN: 0021-9258, DOI: 10.1074/jbc.M113.485847
  • D'AMICO FABIO ET AL: "S100A7: A rAMPing up AMP molecule in psoriasis", CYTOKINE AND GROWTH FACTOR REVIEWS, ELSEVIER LTD, GB, vol. 32, 25 January 2016 (2016-01-25), pages 97 - 104, XP029821544, ISSN: 1359-6101, DOI: 10.1016/J.CYTOGFR.2016.01.002
  • MARIAGRAZIA GRANATA ET AL: "S100A7, Jab1, and p27 kip1 expression in psoriasis and S100A7 CRISPR-activated human keratinocyte cell line", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 120, no. 3, 11 September 2018 (2018-09-11), pages 3384 - 3392, XP055620096, ISSN: 0730-2312, DOI: 10.1002/jcb.27609
  • CALANDRA, THIERRY ET AL.: "Macrophage Migration Inhibitory Factor: A Regulator of Innate Immunity", NATURE REVIEWS IMMUNOLOGY, vol. 3, 2003, pages 79, XP055430236
  • WEBB, MEGHAN ET AL.: "Expression Analysis of the Mouse S 100A7 /psoriasin Gene in Skin Inflammation and Mammary Tumorigenesis", BMC CANCER, vol. 5, 2005, pages 1 - 16, XP021004775
  • EMBERLEY, ETHAN D. ET AL.: "The S 100A7 -c-Jun Activation Domain Binding Protein 1 Pathway Enhances Prosurvival Pathways in Breast Cancer", CANCER RESEARCH, vol. 65, no. 13, 2005, pages 5696 - 5702, XP055533222
  • GESSER, B.: "Dimethylfumarate Inhibits MIF-induced Proliferation of Keratinocytes by Inhibiting MSK1 and RSK1 Activation and by Inducing Nuclear pc-Jun (S63) and p-p53 (S15) Expression", INFLAMMATION RESEARCH, vol. 60, 2011, pages 643 - 653, XP019916954
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).